by CheckRare Staff | Jul 28, 2023
Jennifer Puck, Professor of Pediatrics at the University of California, San Francisco, and co-leader of Rare Diseases Clinical Research Network’s (RDCRN) Primary Immune Deficiency Treatment Consortium, and Monica Thakar, MD, Associate Professor at both Fred...
by Madaline Spencer and Peter Ciszewski | Jul 27, 2023
Courtney Silverthorn, Ph.D., Associate Vice President for Science Partnerships at the Foundation for the National Institutes of Health (FNIH), discusses the recent announcement that the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has...
by Madaline Spencer | Jul 26, 2023
Milan Radovich, PhD, Chief Scientific Officer at Caris Life Sciences, discussed the use of artificial intelligence (AI) to improve the diagnosis of different cancer patients. Each patient’s imaging data, electronic health records, exome sequencing data, etc.,...
by Madaline Spencer and Peter Ciszewski | Jul 20, 2023
Rennie McCarthy, Chief Executive Officer at Stealth Biotherapeutics, provides an overview of mitochondrial myopathy, or myopathic mitochondrial DNA depletion syndrome. Mitochondrial myopathy is a rare genetic disorder caused by mutations in nuclear...
by CheckRare Staff | Jul 19, 2023
Richard Lafayette, MD, FACP, Director of the Stanford Glomerular Disease Center, and Rheumatologist at Stanford Health Care, describes the latest clinical trial assessing Nefecon (budesonide delayed-release capsules) for immunoglobulin A (IgA) nephropathy treatment....
